1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014

Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 17 pages

Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014’, provides an overview of the Sinil Pharmaceutical Co., Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sinil Pharmaceutical Co., Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sinil Pharmaceutical Co., Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sinil Pharmaceutical Co., Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Sinil Pharmaceutical Co., Ltd’s pipeline products

Reasons to buy

- Evaluate Sinil Pharmaceutical Co., Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sinil Pharmaceutical Co., Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sinil Pharmaceutical Co., Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sinil Pharmaceutical Co., Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sinil Pharmaceutical Co., Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sinil Pharmaceutical Co., Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014
Table of Contents

Sinil Pharmaceutical Co., Ltd Snapshot 4
Sinil Pharmaceutical Co., Ltd Overview 4
Key Information 4
Key Facts 4
Sinil Pharmaceutical Co., Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
Sinil Pharmaceutical Co., Ltd - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Sinil Pharmaceutical Co., Ltd - Pipeline Products Glance 9
Sinil Pharmaceutical Co., Ltd - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Sinil Pharmaceutical Co., Ltd - Drug Profiles 11
SI-000513 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
SI-001002 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Drug for Undisclosed Indication 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
SI-000701 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Sinil Pharmaceutical Co., Ltd - Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
Coverage 16
Secondary Research 16
Primary Research 16
Expert Panel Validation 16
Contact Us 17
Disclaimer 17

List of Tables

Sinil Pharmaceutical Co., Ltd, Key Information 4
Sinil Pharmaceutical Co., Ltd, Key Facts 4
Sinil Pharmaceutical Co., Ltd - Pipeline by Indication, 2014 6
Sinil Pharmaceutical Co., Ltd - Pipeline by Stage of Development, 2014 7
Sinil Pharmaceutical Co., Ltd - Monotherapy Products in Pipeline, 2014 8
Sinil Pharmaceutical Co., Ltd - Preclinical, 2014 9
Sinil Pharmaceutical Co., Ltd - Discovery, 2014 10

List of Figures

Sinil Pharmaceutical Co., Ltd - Pipeline by Stage of Development, 2014 7
Sinil Pharmaceutical Co., Ltd - Monotherapy Products in Pipeline, 2014 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.